External reports (aggregated public sources), Value Investors Club

Value Investors Club

External reports (aggregated public sources)

Equity Bottom-Up

<ul><li>SPRB is developing tildacerfont, a second-generation CRF1 antagonist for CAH treatment</li><li>Recent Phase 2 trial failure doesn't negate potential, but upcoming trial results are more relevant</li><li>Market overreaction to negative news creates attractive opportunity for investors, with upside potential and downside protection for SPRB</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>

SPRB is developing tildacerfont, a second-generation CRF1 antagonist for CAH treatmentRecent Phase 2 trial failure doesn't negate potential, but upcoming trial results are more relevantMarket overreaction to negative news creates attractive opportunity for investors, with upside potential and downside protection for SPRBThis content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Spruce Biosciences Inc (SPRB) - Friday, Mar 22, 2024

United States

Spruce Biosciences, Inc. operates as a biotechnology company. The Company offers endocrinology and orphan drug development to meet the unmet need of patients suffering from endocrine disorders. Spruce Biosciences serves patients in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Spruce Biosciences (SPRB US)

Spruce Biosciences Inc (SPRB) - Friday, Mar 22, 2024

SPRB is developing tildacerfont, a second-generation CRF1 antagonist for CAH treatment. Recent Phase 2 trial failure doesn't negate potential, but...

Value Investors Club

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)